Amgen plans to simultaneously develop three oncology drugs, the most advanced of them being Motesanib, which is being developed in collaboration with the Tokyo-based Takeda Pharmaceutical.
Referring to the two forms of denosumab the company is now marketing, Amgen chairman and CEO Kevin Sharer said after working for 15 years, investing a billion and a half dollars and overcoming many challenges, they brought to market two very important medicines that we are very optimistic about.
Bloomberg.com has quoted Amgen chief medical officer Sean Harper as saying that he feels very good about the fact that they haven’t built an oncology-focused pipeline, it’s a healthy proportion of their pipeline.